Test Background Dabigatran is a direct thrombin inhibitor (DTI) which exerts its anticoagulant effect through its ability to directly inhibit Thrombin. Plasma Dabigatran levels are measured in mass concentration by dilute thrombin time assay using drug-specific calibrators.
Recommended as an option for (NICE Guidelines 2016 – KTT16)
• Prevention of VTE after elective hip or knee replacement
• Treatment and secondary prevention of DVT and/or PE
• Prevention of stroke and systemic embolism in people with non-valvular AF
Dabigatran monitoring is not generally required; however measurement may be useful where clearance is compromised or where patients are actively bleeding.
BCSH Guidelines (2014) Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis:
Dose Peak mean Trough mean
Dabigatran 150 mg bd 0.18 ug/mL (0.06 – 0.44) 0.09 ug/mL (0.03 – 0.23)
Sample Required 4.5 mL sodium citrate (pale blue top) adults 1.8 mL sodium citrate (pale blue top) paediatrics
<24 hours (core hours)
Notes Please Note: Samples will be rejected if under/over-filled, clotted or haemolysed